# NCT05281406 (NCT05281406)

> Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05281406
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Goethe University
- Conditions: NSCLC Stage IIIB; NSCLC Stage IV
- Interventions: Osimertinib; Pemetrexed; Cisplatin; Carboplatin
- Enrollment: 50
- Primary outcome: Progression Free Survival (PFS1)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05281406